DCRI Collaborates with Biotechnology Partners to Promote Innovation in Precision Health
The Precision Health Alliance, a new consortium co-founded by the Duke Clinical Research Institute (DCRI), Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Verve Therapeutics, launched today to promote innovation in precision health and medicine. Additional academic and industry collaborators are expected to join the alliance in the future.
Study Shows Alarming Rise in Heart Failure Deaths, Especially Among Younger Adults
After decades of decline, heart failure mortality is climbing, with a dramatic rise in heart failure deaths among younger adults. The number of people dying from heart failure in the United States went down steadily from 1999 to 2009. However, progress made in treating heart failure began unraveling from 2009 to 2012 when heart failure-related mortality rates plateaued, according to a study led by Duke University School of Medicine.
Drug Development for Major Chronic Health Conditions–Aligning With Growing Public Health Needs
Read insights from a recent DCRI Think Tanks where experts discussed the current state of drug development for chronic health conditions, identified key barriers, and formulated six action items to accelerate drug development.
New Partnership for Metabolic Platform to Accelerate Weight Loss Research and Treatment
The Duke Clinical Research Institute (DCRI) and the Duke Margolis Institute for Health Policy are working to establish a platform for characterizing obesity management patterns and treatment responses while addressing barriers to clinical trials integrated into patients’ point-of-care experience. This new initiative — known as the Platform for Evidence GeneraTion in Cardiometabolic HeaLth (PETAL) — is a collaborative effort with Eli Lilly and Company to better understand the landscape of weight loss research and treatment.
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
DCRI is the world’s largest academic clinical research organization and a pioneer in cardiovascular clinical research, combining clinical an
ACC 2024: DCRI faculty share cardiovascular expertise as part of more than 100 sessions over three days
APRIL 15, 2024 — Faculty experts from the Duke Clinical Research Institute (DCRI) shared insights and expertise on the latest cardiology research as part of more than 100 late-breaking
EMPACT-MI: Therapy Shows Promise in Delaying Hospitalizations for Heart Failure
About 800,000 people in the U.S. suffer a heart attack every year, and about 30% of them will go on to develop heart failure. There are limited treatments to prevent or slow that development.
Fortified Eggs Did Not Raise Cholesterol in Modest-Sized Cardiology Study
There are often conflicting headlines about whether certain foods are good or bad for you, and the news about eggs has been especially confusing. Search the topic online and you’ll find a wealth of articles spanning back decades.
Scale That Measures Fluid Retention Improves Prediction of Heart Failure Events
DCRI News from Technology and Heart Failure Therapeutics 2024
International Partnership Formed to Fight Antibacterial Resistance
The Antibacterial Resistance Leadership Group (ARLG), the European Clinical Research Alliance on Infectious Diseases (Ecraid), and ADVANcing Clinical Evidence in Infectious Diseases (ADVANCE-ID) Network have joined forces to create a global alliance against antibacterial resistance.